Ned Sharpless would be designated as a FDA commissioner working


WASHINGTON – named an administrator of Trump Tuesday that he would nominate Ned Sharpless, director of the National Institute, the commissioner for the Food and Drug Administration next month.

The film came just a week after his current commissioner, Scott Gottlieb, had announced his retirement in early April.

Health secretary Alex Azar confirmed the message at a hearing before the Energy and House Energy sub-committee. This news was first published by Fox Business Network.

an advertisement

Sharpless, a physician, operated Cancer Cancer Center at University of North Carolina before taking over the NCI in October 2017.

“Dr. Sharpless's history and scientific knowledge become a strong leader for FDA, ”said Azar in a statement. T “The focus of the organization will not be on a continuation, from continuing efforts to drug licensing and opiate crisis combat to refreshing food and to address the rapid increase in young people's use of alcohol. ”

Sharpless was a strong supporter of Gottlieb's attempt to increase tobacco and cigarette regulations.

While it is still uncertain whether Sharpless will be leading the FDA in a long-term capacity, it was seen as a substitute for Gottlieb. Sharpless already knows the organization, Gottlieb, in a staff memorandum given by the FDA to STAT.

“Of course, he plays on a weekly basketball team with some medical review staff,” wrote Gottlieb.

Sharpless is also familiar with the biotechnology industry and the drug development process. He has established two early biotechnology companies: G1 Therapeutics, a cancer drugs therapist who first raised $ 108.6 million in public tender in 2017 and HealthSpan Diagnostics, a blood test therapist. T

“One of the things I have done is drawing in to the White House, as well as working in research and as a director of cancer, that I've had a little bit of work in t exchange ideas, from basic science science to the Level 2 asset test, ”Sharpless told STAT in 2018 interview, shortly after taking over NCI.

Even from his job within the National Health Institutions, Sharpless often spoke about how his organization could work with the FDA – and how, at NCI, its powers of care and development were improving. develop cancer more limited.

He has shown a long interest in using false understanding, including IBM Watson and his cancer care machine, to improve treatments – recognizing that technology is limited. “It is early days for the National Institute for this sector,” he said last year, “most of the governance issues are for the FDA to address. ”

Douglas Lowey, deputy director of NCI, works as director of the cancer research institute and Sharpless works as an executive director of the FDA.

Sharon Begley gave an account.

Source link